ANDA 205191, held by Eugia Pharma. Ketorolac Tromethamine.
As of Nov 21, 2026, ANDA 205191 (Ketorolac Tromethamine), held by Eugia Pharma, was first approved by FDA on Nov 15, 2018, with 1 approved supplement and 0 published complete response letters.
Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 15, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ketorolac Tromethamine0.4% · solution/drops;ophthalmic | Ketorolac Tromethamine | Discontinued |
| Mar 29, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 15, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters